CAJ | 학술논문

目的研究肝癌根治性切除术后免疫治疗联合肝动脉化疗栓塞的价值。材料与方法肝癌根治性切除者80例，随机分为两组。肝癌根治性切除术后免疫治疗联合肝动脉化疗栓塞40例为观察组；肝癌根治性切除术后单纯免疫治疗40例为对照组。对两组病例1年、2年的肝内复发率和生存率分别作χ2检验，进行对照分析。结果观察组1年、2年的肝内复发率分别为12.5%(5/40)、30.0%(12/40)，较对照组32.5%(13/40)、52.5%(21/40)降低(χ2值分别为4.59、4.18，P值均＜0.05)；观察组1年、2年的生存率分别为85.0%(34/40)、70.0%(28/40)，较对照组65.0%(26/40)、47.5%(19/40)提高(χ2值分别为4.27、4.18，P值均＜0.05)。结论肝癌根治性切除术后免疫治疗联合肝动脉化疗栓塞是控制肝内复发率，提高患者生存率的有价值的治疗方法。
목적연구간암근치성절제술후면역치료연합간동맥화료전새적개치。재료여방법간암근치성절제자80례，수궤분위량조。간암근치성절제술후면역치료연합간동맥화료전새40례위관찰조；간암근치성절제술후단순면역치료40례위대조조。대량조병례1년、2년적간내복발솔화생존솔분별작χ2검험，진행대조분석。결과관찰조1년、2년적간내복발솔분별위12.5%(5/40)、30.0%(12/40)，교대조조32.5%(13/40)、52.5%(21/40)강저(χ2치분별위4.59、4.18，P치균＜0.05)；관찰조1년、2년적생존솔분별위85.0%(34/40)、70.0%(28/40)，교대조조65.0%(26/40)、47.5%(19/40)제고(χ2치분별위4.27、4.18，P치균＜0.05)。결론간암근치성절제술후면역치료연합간동맥화료전새시공제간내복발솔，제고환자생존솔적유개치적치료방법。
Objective　To evaluate immunotherapy combined with hepatic chemoembolization in the treatment of liver cancer after radical operation.　Materials and Methods　Eighty patients who had received radical operation for liver cancer were equally divided into two groups: (1) study group, receiving immunotherapy together with hepatic chemoembolization; (2) control group, receiving immunotherapy only. Intrahepatic recurrence rate and survival rate at one and 2 years after the treatment in both groups were analyzed and compared by using χ2 testing. 　Results　The intrahepatic recurrence rate (and the survival rate) at one and 2 years of the study group and control group was 12.5%, 30.0% (85.0%, 70.0%) and 32.5%, 52.5% (65.0%, 47.5%), with the χ2 value of 4.59 and 4.18 (4.27 and 4.18)), respectively (P＜0.05).　Conclusion　A combination of immunotherapy and hepatic chemoembolization for liver cancer after radical surgery is an effective treatment, it can reduce the intrahepatic recurrence rate and increase the survival rate.